Timothy Sullivan - Apr 25, 2022 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role: Chief Financial Officer
Signature: /s/s David Watson, attorney-in-fact for Timothy Sullivan
Stock symbol: APLS
Transactions as of: Apr 25, 2022
Transactions value $: $2,274,017
Form type: 4
Date filed: 1/17/2023, 07:00 PM
Previous filing: Feb 14, 2022
Next filing: Jan 24, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	APLS	Common Stock	Other	$0	-3.75K	-3.63%	$0.00	99.7K	Apr 25, 2022	Direct	F1
transaction	APLS	Common Stock	Award	$0	+27.5K	+27.58%	$0.00	127K	Jan 12, 2023	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	APLS	Stock Option (Right to Buy)	Other	$0	-22.5K	-100%	$0.00^*	0	Apr 25, 2022	Common Stock	22.5K	$44.90	Direct	F3, F4
transaction	APLS	Stock Option (Right to Buy)	Award	$2.27M	+43.2K		$52.66	43.2K	Jan 12, 2023	Common Stock	43.2K	$52.66	Direct	F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This represents the cancellation of a PSU awards granted on 01/28/2021 that was originally reported in table I upon grant. The performance metrics were not met.
F2	This represents a Restricted Stock Award granted 01/12/23 that vest annually from grant date over a four year period subject to continued service.
F3	This represents the cancellation of a performance stock option granted on 01/28/2021. The performance metrics were not met.
F4	This stock option will vest as to 25% of the shares underlying the options on the first anniversary of the grant, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to the satisfaction of a specified performance condition and continued service.
F5	This represents a stock option award granted 01/12/2023 that vest over a four year period. 25% vest one year from grant date and the remaining 75% vest monthly thereafter subject to continued service.